SCHEDULE: Vanguard Reports 0% Stake in Regeneron Post-Realignment
Beneficial Ownership Update
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Regeneron Pharmaceuticals Inc. following an internal realignment where subsidiaries will now report separately.
Summary
- The Vanguard Group filed an Amendment No. 7 to its Schedule 13G for Regeneron Pharmaceuticals Inc. (CUSIP: 75886F107).
- As of March 13, 2026, The Vanguard Group reports 0% beneficial ownership of Regeneron's Common Stock, with no sole or shared voting or dispositive power.
- This change stems from an internal realignment within The Vanguard Group, effective January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
- These subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative update regarding The Vanguard Group's internal reporting structure, with no direct impact on Regeneron Pharmaceuticals Inc.'s operational or financial performance.
Future Outlook
No forward-looking statements or guidance regarding Regeneron Pharmaceuticals Inc.'s business or financial performance are provided in this administrative filing.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are used by passive investors, such as large asset managers like The Vanguard Group, to report beneficial ownership of 5% or more of a company's stock. This amendment reflects an internal organizational change at Vanguard, where its subsidiaries will now report their holdings separately, rather than a change in Vanguard's overall investment strategy or a divestment from Regeneron. This disaggregated reporting by subsidiaries is a common practice for large institutional investors to comply with SEC regulations.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Structure | The Vanguard Group underwent an internal realignment, leading to its subsidiaries and/or business divisions reporting beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538. | 2026-01-12 | This change affects how Vanguard's aggregate beneficial ownership is reported to the SEC, shifting the reporting responsibility to individual subsidiaries for specific holdings, but does not alter the underlying investment strategies or control of the issuer. |
Stakeholder Impact
- Shareholders: May need to track beneficial ownership from multiple Vanguard entities instead of a single consolidated report for Regeneron Pharmaceuticals Inc.
- Investment Professionals: Requires awareness of Vanguard's new disaggregated reporting approach when analyzing institutional ownership data for Regeneron Pharmaceuticals Inc.
Key Dates
| Date | Description |
|---|---|
| 2026-01-12 | Effective date of The Vanguard Group's internal realignment, leading to disaggregated beneficial ownership reporting by subsidiaries. |
| 2026-03-13 | Date of event requiring the filing of this Schedule 13G Amendment No. 7 for Regeneron Pharmaceuticals Inc. |
| 2026-03-27 | Date of signing of the Schedule 13G Amendment No. 7 by Ashley Grim, Head of Global Fund Administration for The Vanguard Group. |
Keywords
Vanguard Group, Regeneron Pharmaceuticals, Schedule 13G, beneficial ownership, internal realignment, investment adviser, SEC filing, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.